ABUS - Arbutus Biopharma Corporation
| Previous Close | 2.3300 |
| Open | 2.3200 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 2200 |
| Day's Range | 2.0800 - 2.3300 |
| 52 Week Range | 2.0800 - 12.6000 |
| Volume | 326,492 |
| Avg. Volume | 294,514 |
| Market Cap | 118.817M |
| Beta (3Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3220 |
| Earnings Date | Mar 13, 2019 - Mar 20, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- Simply Wall St.•14 hours ago
Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine...
- GlobeNewswire•10 days ago
Arbutus to Present at Upcoming May 2019 Conferences
WARMINSTER, Pa., May 13, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks•16 days ago
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•16 days ago
Arbutus: 1Q Earnings Snapshot
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 47 cents. The biopharmaceutical company posted revenue of $700,000 in the period. In the final minutes of trading ...
- GlobeNewswire•16 days ago
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019.
- GlobeNewswire•24 days ago
Arbutus to Report First Quarter 2019 Financial Results
WARMINSTER, Pa., April 29, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks•28 days ago
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•last month
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
- Zacks•last month
Top Ranked Momentum Stocks to Buy for April 8th
Top Ranked Momentum Stocks to Buy for April 8th
- Simply Wall St.•2 months ago
Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Arbutus Biopharma Corporation (NASDAQ:ABUS) released its latest earnings announcement, which signalled...
Motley Fool•2 months agoArbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
ABUS earnings call for the period ending December 31, 2018.
- GlobeNewswire•2 months ago
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a.
- GlobeNewswire•3 months ago
Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 28, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•4 months ago
Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register?
If you want to know who really controls Arbutus Biopharma Corporation (NASDAQ:ABUS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...
- Insider Monkey•5 months ago
Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- GlobeNewswire•5 months ago
New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Insider Monkey•5 months ago
Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy?
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
- Simply Wall St.•6 months ago
Why Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To You
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- GlobeNewswire•6 months ago
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. For much of his career, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm.
- Zacks•6 months ago
Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
Arbutus (ABUS) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•6 months ago
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug.
- GlobeNewswire•7 months ago
Arbutus to Report Third Quarter 2018 Financial Results
WARMINSTER, Pa., Oct. 31, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
